Avvisa Prohibits Advertising of the Semavy Pen - 25/09/2026
4 Articles
4 Articles
Disclosure The National Agency for Health Surveillance (Anvisa) banned the advertising of Semavy, a semiglutide-based pen indicated for the treatment of type 2 diabetes. The decision was published in the Official Journal of the Union and released by the agency on Friday (25). According to Anvisa, the drug had been irregularly announced to the general public, including electronic panels at Congonhas Airport, in São Paulo, in addition to the produ…
The measure was published on Friday (25) in the DOU (Official Journal of the Union) The post Semavy enters the sights of Anvisa: agency prohibits pen advertising with semaglutide; understand why the medicine cannot be announced apareceu primeiro em ND More
The drug was being disseminated to the general public through electronic panels at Congonha Airport and on social networks
After identifying irregular advertisements of the slimming pen Semavy, Anvisa (National Agency for Health Surveillance) decided to edit a more drastic measure and prohibit drug advertisements. Read more (09/25/2026)
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
